(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Part of paid clinical trials in Goodyear, Arizona.

Sponsor
Western Regional Medical Center
Study ID
NCT01936974
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine — DRUG
    Patient to receive gemzar
  • Bevacizumab — DRUG
    Patient to receive avastin
  • Carboplatin — DRUG
    Patient to receive carboplatin
  • Cisplatin — DRUG
    Patient to receive cisplatin
  • Oxaliplatin — DRUG
    Patient to receive Oxaliplatin

Study Details

To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma

Key Dates

First listed
Sep 6, 2013
Start date
Sep 30, 2013
Status verified
Jan 2018
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
7 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Platinum, Gemcitabine and Bevacizumab
    Platinum: 1. Carboplatin\* on day 1 \*If a patient is allergic to carboplatin, then give 2. Cisplatin\*\* on day 1 \*\*If a patient is allergic to cisplatin and carboplatin, then give 3. Oxaliplatin on day 1 Gemcitabine on day 1 only Bevacizumab on day 1
  • Active Comparator: Gemcitabine and Bevacizumab
    Gemcitabine on days 1 and 8 Bevacizumab on day 1

Primary Outcome Measure

Progression-free Survival [ Time Frame: One Year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Western Regional Medical CenterGoodyearArizona85338-

Find similar trials in Goodyear, AZ

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Western Regional Medical Center· Goodyear, AZ

Related Studies